Top Story

High compliance with Optune linked to greatest survival benefit for glioblastoma

November 17, 2017

Patients with newly diagnosed glioblastoma who used the Optune device more than 90% of the time had the greatest chance for survival, according to a company-issued press release.

Optune (Novocure) is a portable device that delivers tumor-treating-fields — or low-intensity, alternating electrical fields — through electrodes placed on the surface of the patient’s scalp. Rapidly dividing tumor cells may be susceptible to damage when exposed to tumor-treating fields, thus halting tumor growth.

Meeting News

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

November 16, 2017
WASHINGTON — When diagnosed with Hodgkin lymphoma at…
In the Journals PlusPerspective

Lomustine, bevacizumab fail to improve OS in progressive glioblastoma

November 16, 2017
The addition of lomustine to bevacizumab failed to confer a survival advantage for the treatment of progressive glioblastoma, according to results of a phase 3 EORTC…
FDA News

FDA authorizes IMPACT test to rapidly identify cancer mutations

November 15, 2017
The FDA today authorized Integrated Mutation Profiling of Actionable Cancer Targets, or IMPACT, an in vitro diagnostic test that uses next-generation sequencing to…
More Headlines »

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
Meeting News Coverage

VIDEO: Merge of immunotherapy, genomics leads to personalized treatment

June 23, 2016
More »
Resource Centers


Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »